

Special Issue

Integrating Neoadjuvant Immunotherapy and Surgery for NSCLC: From Biomarkers to Optimized Resection Tactics

Message from the Guest Editors

The advent of neoadjuvant chemo-immunotherapy (chemo-IO) in Non-Small Cell Lung Cancer (NSCLC) has created a complex and dynamic therapeutic space. To maximize patient benefit, success hinges not only on the systemic therapy response but also on precision surgery in a biologically altered environment. We will dedicate equal weight to two critical domains. The first 50% focuses on the oncological and translational science, including identifying optimal regimens, predicting pathological response (MPR/pCR), and utilizing biomarkers such as ctDNA and PD-L1. The remaining 50% will address surgical and clinical challenges, such as managing tissue fibrosis, defining the extent of resection (sublobar vs. lobectomy), and refining operative tactics to ensure safety and efficacy. This collection is highly valuable as it reflects the current state of the art in thoracic oncology, serving as a definitive reference for the entire multidisciplinary team. I warmly invite you to submit your original research and reviews.

Guest Editors

Dr. Piergiorgio Solli

Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Dr. Giovanni Leuzzi

Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/264653

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)